Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study).

No abstract is available for this paper.

• Publication year

  2017

• Venue

  American Journal of Cardiology

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjcard.2017.12.011PMID 29361285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2017cited by this paper
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2017cited by this paper
• 2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary

  2016cited by this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2016cited by this paper
• Cardiovascular risk estimation in older persons: SCORE O.P.

  2016cited by this paper
• Assessment of risk factors for developing incident aortic stenosis: the Tromsø Study

  2014cited by this paper
• Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis.

  2014cited by this paper
• Genetic associations with valvular calcification and aortic stenosis.

  2013cited by this paper
• Guidelines on the management of valvular heart disease (version 2012).

  2012cited by this paper
• Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

  2012cited by this paper
• Molecular Imaging Insights Into Early Inflammatory Stages of Arterial and Aortic Valve Calcification

  2011cited by this paper
• Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial

  2010cited by this paper
• Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy.

  2009cited by this paper
• Calcific aortic stenosis: lessons learned from experimental and clinical studies.

  2009cited by this paper
• Lowering Plasma Cholesterol Levels Halts Progression of Aortic Valve Disease in Mice

  2009cited by this paper
• Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies

  2008cited by this paper
• Review: Does lowering cholesterol have an impact on the progression of aortic stenosis?

  2008cited by this paper
• Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

  2008cited by this paper
• Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology

  2007cited by this paper
• Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.

  2007cited by this paper
• Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.

  2007cited by this paper
• Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio

  2005cited by this paper
• A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.

  2005cited by this paper
• Atorvastatin Inhibits Hypercholesterolemia-Induced Calcification in the Aortic Valves via the Lrp5 Receptor Pathway

  2005cited by this paper
• Human Aortic Valve Calcification Is Associated With an Osteoblast Phenotype

  2003cited by this paper
• The response-to-retention hypothesis of early atherogenesis.

  1995cited by this paper

• Novel Circulating Biomarkers in Aortic Valve Stenosis

  2025cites this paper
• Association of ankle-brachial Index with coronary and extra-coronary calcification in older adults: ARIC study

  2025cites this paper
• Valvular Interstitial Cells as a novel therapeutic target for preventing Calcific Aortic Valve Disease.

  2025cites this paper
• Aortic Valve Calcium Score: Applications in Clinical Practice and Scientific Research—A Narrative Review

  2024cites this paper
• Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial

  2024cites this paper
• Causal associations between kidney function and aortic valve stenosis: a bidirectional Mendelian randomization analysis

  2024cites this paper
• Prevalence of Aortic Valve Calcium and the Long-Term Risk of Incident Severe Aortic Stenosis.

  2023cites this paper
• Understanding the driving mechanisms of bioprosthetic valve degeneration

  2023cites this paper
• Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023

  2023cites this paper
• Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?

  2022cites this paper
• The sweet development and progression of aortic stenosis

  2022cites this paper
• Novel Insights Into Identifying Patients at Risk for Developing Calcific Aortic Stenosis: Clinical Implications.

  2022cites this paper
• Cellular Senescence, Aging and Non-Aging Processes in Calcified Aortic Valve Stenosis: From Bench-Side to Bedside

  2022cites this paper
• Obesity, Triglycerides, Remnant Cholesterol, and Other Causal Factors in Aortic Valve Stenosis: A Review

  2022cites this paper
• The Lp(a)/BMI Gradient in Osteocardiology: The Copenhagen Connection.

  2022cites this paper
• The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases

  2021cites this paper
• Rate of Progression of Aortic Stenosis in Patients With Cancer

  2021cites this paper
• Lipoprotein(a) is robustly associated with aortic valve calcium

  2021cites this paper
• Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association

  2021cites this paper
• Acquired Valvular Heart Disease: Overview of Patient Population

  2021cites this paper
• Lipid levels linked to symptomatic aortic valve stenosis: evidence from Mendelian randomization?

  2020cites this paper
• Bench to bedside defining calcific aortic valve disease: osteocardiology

  2020cites this paper
• Limitations of subgroup analysis of underpowered clinical trials for making causal inference about treatment effects.

  2020cites this paper
• High low-density lipoprotein levels and high risk of aortic stenosis.

  2020cites this paper
• Calcified Aortic Valve Disease in Patients With Familial Hypercholesterolemia.

  2020cites this paper
• The progression rate of aortic stenosis: key to tailoring the management and potential target for treatment

  2020cites this paper
• Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.

  2019cites this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis

  2019cites this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy

  2019cites this paper
• LDL-cholesterol: The lower the better.

  2019cites this paper
• Bone and cartilage metaplasia in calcific aortic stenosis

  2019cites this paper
• Adding ezetimibe to statin therapy: latest evidence and clinical implications

  2018cites this paper
• Degenerative Aortic Stenosis, Dyslipidemia and Possibilities of Medical Treatment

  2018cites this paper